Back to top

Analyst Blog

Mylan Inc. (MYL - Analyst Report) recently announced that the Court of Appeals for the Federal Circuit has issued a favorable verdict for the company in a patent infringement case. The court overturned the decision of the District Court invalidating five of Mylan's patents related to its chronic obstructive pulmonary disease (COPD) drug Perforomist. Following the favorable court decision, Mylan’s patents regarding Perforomist stand as valid and enforceable.

In 2012, Mylan settled its patent dispute with Sunovion Pharmaceuticals Inc., a subsidiary of Japanese pharmaceutical company, Dainippon Sumitomo Pharma Co., Ltd. pertaining to Sunovion's Brovana, pending the result of the Federal Circuit appeal. Sunovion recognized that Brovana infringed two of Mylan’s patents, which are valid till Jun 22, 2021. Brovana is approved for controlling the symptoms of COPD, including chronic bronchitis and emphysema. Both Brovana and Perforomist are long-acting beta-2 agonists.

We note that the Perforomist inhalation solution is marketed by the Mylan Specialty segment. The drug performed well in the first quarter of 2013. The most significant product in this segment is EpiPen auto-injector, which is used to treat severe allergic reactions.

The bulk of the revenues  come from its generic division. The company’s generics business has been consistently performing well. Mylan’s generic unit has seen quite a few launches over the past few months. Important recent launches include the company's generic version of Valeant Pharmaceuticals' (VRX - Snapshot Report) Zovirax ointment.  Dr. Reddy's Laboratories Ltd. (RDY - Analyst Report) too has been making multiple generic launches over the past few months.

Mylan carries a Zacks Rank #3 (Hold). Lannett Company, Inc. (LCI - Snapshot Report) appears to be more attractive with a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%